Raymond James & Associates’s Dyne Therapeutics DYN Stock Holding History

Raymond James & Associates’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.76M	Sell	49,027 -51,723	-51%	-$2.06M	﹤0.01%	2300
2024 Q2	$3.56M	Sell	100,750 -68,213	-40%	-$1.98M	﹤0.01%	1814
2024 Q1	$4.8M	Buy	168,963 +82,466	+95%	+$1.87M	﹤0.01%	1611
2023 Q4	$1.15M	Sell	86,497 -1,741	-2%	-$17K	﹤0.01%	2435
2023 Q3	$791K	Buy	88,238 +16,240	+23%	+$175K	﹤0.01%	2610
2023 Q2	$810K	Sell	71,998 -5,205	-7%	-$61.4K	﹤0.01%	2610
2023 Q1	$889K	Buy	77,203 +21,836	+39%	+$284K	﹤0.01%	2519
2022 Q4	$642K	Sell	55,367 -2,840	-5%	-$32.9K	﹤0.01%	2717
2022 Q3	$739K	Buy	+58,207	New	+$667K	﹤0.01%	2583

Other funds holding DYN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Raymond James & Associates's DYN Position: Q3 2024 in Review

Raymond James & Associates reduced its Dyne Therapeutics (DYN) stake by 51% in Q3 2024, selling an estimated $2.06M and leaving 49,027 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2300.

Raymond James & Associates first reported a position in DYN in Q3 2022 and has held it in 9 quarters since. The position peaked at $4.8M in Q1 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q3 2024.

Raymond James & Associates held 49,027 shares of Dyne Therapeutics worth $1.76M as of Q3 2024.
Raymond James & Associates sold 51,723 Dyne Therapeutics shares in Q3 2024, an estimated $2.06M.
Dyne Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2300 holding.
Raymond James & Associates first reported a position in Dyne Therapeutics in Q3 2022 and has held it in 9 quarters since.
Raymond James & Associates's Dyne Therapeutics position peaked at $4.8M in Q1 2024.
200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.